Filing Details
PDS Biotechnology Corp (NASDAQ:PDSB) filed a Form 8-K with the Securities and Exchange Commission on August 13, 2026, disclosing a material event.
8k filedNASDAQ:PDSB
PDS Biotechnology Corp (PDSB) Reports Material Event to SEC
PDS Biotechnology Corp (NASDAQ:PDSB) filed a Form 8-K with the Securities and Exchange Commission on August 13, 2026, disclosing a material event.
At publication ·
What changed
PDS Biotechnology Corp (NASDAQ:PDSB) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- PDS Biotechnology Corp filed a Form 8-K with the SEC on August 13, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this filing summary.
- The company's stock trades at $0.23 per share with a market capitalization of $49.9 million as of the filing date.
- Material events reported on Form 8-K can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance, and investors can access all SEC filings through the EDGAR database.
Market Context
PDS Biotechnology Corp's stock currently trades at $0.23 with a market capitalization of $49.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for PDS Biotechnology Corp's stock.
All SEC filings for PDS Biotechnology Corp are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PDSB Stock Page
Frequently Asked Questions
Where can I read PDSB's SEC filings?
Browse all filings on our PDSB SEC filings page.
What types of SEC filings does PDS Biotechnology Corp file?
Public companies like PDS Biotechnology Corp file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.